CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← SPRUCE BIOSCIENCES, INC. (SPRB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

SPRUCE BIOSCIENCES, INC. (SPRB)

Pharmaceutical Preparations · market cap $136M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Spruce Biosciences (SPRB) is a clinical-stage pharmaceutical company with a market cap of ~$138M and 9 employees, built around a single asset: SPR001, a Phase 2 candidate for Congenital Adrenal Hyperplasia (CAH). The company holds ~$54.1M in cash with an estimated 18.6-month runway, and the next formal public touchpoint is an August 13, 2026 earnings call.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
SPR001Phase 2Congenital Adrenal Hyperplasia
Price & technical context
3-month
-18.2%
6-month
-19.5%
12-month
-57.6%
52-wk range
$38.98–$115.00
vs 50-day MA
-8.3%
vs 200-day MA
-19.9%
Realized vol
85.2%
Max drawdown
-99.8%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for SPRB (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.